Leptin, skeletal muscle lipids, and lipid-induced insulin resistance.
Leptin-induced increases in insulin sensitivity are well established and may be related to the effects of leptin on lipid metabolism. However, the effects of leptin on the levels of lipid metabolites implicated in pathogenesis of insulin resistance and the effects of leptin on lipid-induced insulin resistance are unknown. The current study addressed in rats the effects of hyperleptinemia (HL) on insulin action and markers of skeletal muscle (SkM) lipid metabolism in the absence or presence of acute hyperlipidemia induced by an infusion of a lipid emulsion. Compared with controls (CONT), HL increased insulin sensitivity, as assessed by hyperinsulinemic-euglycemic clamp ( approximately 15%), and increased SkM Akt ( approximately 30%) and glycogen synthase kinase 3 alpha ( approximately 52%) phosphorylation. These improvements in insulin action were associated with decreased SkM triglycerides (TG; approximately 61%), elevated ceramides ( approximately 50%), and similar diacylglycerol (DAG) levels in HL compared with CONT. Acute hyperlipidemia in CONT decreased insulin sensitivity ( approximately 25%) and increased SkM DAG ( approximately 33%) and ceramide ( approximately 60%) levels. However, hyperlipidemia did not induce insulin resistance or SkM DAG and ceramide accumulation in HL. SkM total fatty acid transporter CD36, plasma membrane fatty acid binding protein, acetyl Co-A carboxylase phosphorylation, and fatty acid oxidation were similar in HL compared with CONT. However, HL decreased SkM protein kinase C theta (PKC theta), a kinase implicated in mediating the detrimental effects of lipids on insulin action. We conclude that increases in insulin sensitivity induced by HL are associated with decreased levels of SkM TG and PKC theta and increased SkM insulin signaling, but not with decreases in other lipid metabolites implicated in altering SkM insulin sensitivity (DAG and ceramide). Furthermore, insulin resistance induced by an acute lipid infusion is prevented by HL.
Dube
John J
JJ
Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Bhatt
Bankim A
BA
Dedousis
Nikolas
N
Bonen
Arend
A
O'Doherty
Robert M
RM
D000208:Acute Disease; D000818:Animals; D002518:Ceramides / Q000378:metabolism*; D004075:Diglycerides / Q000378:metabolism; D004655:Emulsions; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology; D050556:Fatty Acid-Binding Proteins / Q000378:metabolism; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology*; D007527:Isoenzymes / Q000378:metabolism; D020738:Leptin / Q000097:blood / Q000494:pharmacology*; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism*; D010743:Phospholipids; D011493:Protein Kinase C / Q000378:metabolism; D000074121:Protein Kinase C-theta; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012450:Safflower Oil; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013024:Soybean Oil; D014280:Triglycerides / Q000378:metabolism*
D002518:Ceramides; D004075:Diglycerides; D004655:Emulsions; D005217:Fat Emulsions, Intravenous; D050556:Fatty Acid-Binding Proteins; D007328:Insulin; D007527:Isoenzymes; D020738:Leptin; D010743:Phospholipids; D014280:Triglycerides; C063336:safflower oil, soybean oil, phospholipid emulsion; D013024:Soybean Oil; D012450:Safflower Oil; D051057:Proto-Oncogene Proteins c-akt; C489591:Prkcq protein, rat; D011493:Protein Kinase C; D000074121:Protein Kinase C-theta; D038362:Glycogen Synthase Kinase 3; C448021:glycogen synthase kinase 3 alpha